Draft Program

Day 1 | Day 2 | Day 3

On June 5-7, 2014 in San Francisco, CA, the Epilepsy Therapy Project, an initiative of the Epilepsy Foundation will present the 4th Biennial Epilepsy Pipeline Conference 2014, to be held at the Hyatt Regency, San Francisco.

Showcasing the most promising epilepsy therapies from healthcare companies dedicated to pioneering and advancing drugs, biologics, technologies and devices for epilepsy and seizures, this year's conference will feature the third annual "Shark Tank" competition, in addition to a day designated for people with epilepsy, families and advocates. The conference brings together decision-makers with a stake in the field of epilepsy treatment, therapeutic innovation and product development. Speakers and attendees will include emerging biotech and medical technology companies, major pharmaceutical and device companies, and researchers and innovators at the cutting-edge of epilepsy and CNS treatment advances.

Read the press release for more information


Epilepsy Pipeline Conference-June 5-7, 2014
Hyatt Regency
5 Embarcadero Center
San Francisco, CA

onlineRegister Online Today

Questions? Email Us, or Call: 301.918.3740

CONFERENCE HOTEL: Location and Accommodations


Hyatt Regency San Francisco
5 Embarcadero Center
San Francisco, CA 94111
(+1) 415.788.1234

The Epilepsy Foundation has reserved a block of hotel rooms for attendees of the 2014 Epilepsy Pipeline Conference at the event venue, Hyatt Regency – Embarcadero, San Francisco, at the discounted group rate of $239 USD / night (plus applicable taxes). Reservations must be made on or before 05/01/14, or until the block is filled, whichever comes first. Room rate of $239 / night is for Double or King; room upgrades are available at different rates.

A dedicated website is available for booking hotel accommodations. Use the passkey registration link (below) to review options and make your reservation today:

Go to Booking Website:

Poster & Exhibitor Sessions

The Epilepsy Foundation is pleased to announce a call for scientific posters and exhibitors at the 4th Biennial Epilepsy Pipeline Conference 2014. As an exhibitor, you have the opportunity to connect with leaders who attend to learn and to educate other conference participants on the latest advances in epilepsy care and new therapies.

Poster presenters are exempt from the registration fee if the abstract is received by EF before May 1, 2014. Space is limited and is available on a first come, first served basis.

Learn more about submission information, guidelines, and due dates.

With Thanks to Our Supporters

Danny Did Foundation

Resnick Foundation



Draft Conference Agenda

Day 1-Thursday June 5, 2014

7:00-8:00 Registration and Continental Breakfast

SESSION I: Introduction and Keynote Addresses
8:00-8:15 Welcome and Overview Warren Lammert, Chairman, Epilepsy Foundation

Jacqueline French, MD, Professor of Neurology, New York University, Co-director Epilepsy Research and Epilepsy Clinical Trials, NYU Comprehensive Epilepsy Center
2013 Epilepsy Pipeline Scorecard: Pipeline Advances and Challenges
Keynote: Annual State of the Drug Pipeline Jacqueline French, MD; Professor of Neurology, New York University
Keynote: Annual State of the Device Pipeline Robert Fisher, MD, PhD, Professor of Neurology, Director Stanford Comprehensive Epilepsy Program

SESSION II: What was better in 2013 than 2012--Progress in Epilepsy Therapy
FDA and epilepsy trials: Past, Present and Future
Russell Katz, MD
Why Industry Should Keep Investing in Epilepsy
Christopher Gallen, MD, PhD, President and CEO, SK Biopharmaceuticals | SK Life Sciences
The NINDS ASP: Yesterday, Today and Tomorrow
John Kehne, PhD, Program Director, NIH/NINDS

H. Steve White, PhD,
Professor and Director, Anticonvulsant Drug Development Program, University of Utah
Epilepsy Therapies: Accomplishments and Challenges
Roger J. Porter, MD, CSO, Epilepsy Foundation
Networking Break (15 minutes)

SESSION III: Early-Stage Drug Pipeline: Proof of Principle through IND
10:25-10:35 Intellimedix | Platform of computational, in-Silico screening, and then hi-thru put testing in zebra fish with an initial focus on Dravet but broad focus on Epilepsy Daniel Fischer, President and CEO, Intellimedix
Asklepios BioPharmaceutical, Inc. | Galanin gene delivery for temporal lobe epilepsy Cynthia Rask, MD, CMO, Asklepios BioPharmaceutical, Inc.
10:45-10:55 AurimMed Pharma, Inc. | AMP-X-0079 Amir Pesyan, Chairman and CEO, AurimMed Pharma, Inc.
10:55-11:05 BioCrea | LT GABA PAMS for refractory epilepsy Norbert Hoefgen, PhD, VP Discovery, BioCrea
EpaleX | Inhaled Treatment for Refractory Epilepsy Michael A. Rogawski, MD, PhD, Professor, Department of Neurology, University of California, Davis
11:15-11:25 Fluorinov Pharma Inc. | FV-082 Malik Slassi, PhD, President and CSO, Fluorinov Pharma Inc.
11:25-11:35 NeuroGate Therapeutics, Inc. | Extended NeuroAmides Harold Kohn, PhD, Founder, NeuroGate Therapeutics, Inc.
NeuroGenomeX, Inc. | 2DG Thomas P. Sutula, MD, PhD, Founder, CTO and Director, NeuroGenomeX, Inc.
Sage Therapeutics | TBD
Stephen J. Kanes, MD, PhD, CMO, Sage Therapeutics
INSYS Therapeutics, Inc. | Synthetic CBD
Vikram Malhotra, VP Corporate Development and Strategy
12:05-12:15 NeuroAdjuvants, Inc. | Galanin Receptor 2-Based Therapy
12:15-12:30 University of South Florida | Ketogenic Compounds for the Treatment of Epilepsy
Dominic D'Agostino, PhD, Assistant Professor, Hyperbaric Biomedical Research Laboratory
SciFluor Life Sciences LLC | KCNQ2/3
D. Scott Edwards, Vice President and General Manager
12:40-2:10 Networking Lunch and Poster Session (1 hour, 30 minutes)

SESSION IV: Early-Stage Diagnostic Devices and Product Pipeline: New Concepts and Initial Findings
2:10-2:20 Cyberonics | ProGuardian RestTM | An innovative, in-home device systems designed to monitor, detect, and log night-time seizure activity Laurie Groven, Global Medical Device / Diagnostic Marketing and Sales Executive, Cyberonics
2:20-2:30 BrainSentinel | EMG Based Convulsive Seizure Detection and Warning System Jose E. Cavazos, MD, PhD, VP, Medical Affairs, Brain Sentinel, LGCH, Inc.
2:30-2:40 Epitel, Inc. | Wireless EEG Patch Mark Lehmkuhle, PhD, CEO, CTO, Epitel, Inc.
2:40-2:50 Massachusetts Institute of Technology | EpiBand: Electrodermal and Seizure Event Alert Rosalind W. Picard, Sc.D., MIT Media Laboratory, Director of Affective Computing Research, Co-Founder, Affectiva, Inc.
2:50-3:00 Smart Monitor | Automated Seizure Tracking and Recording Anoo Nathan, CEO, Smart Monitor
3:00-3:10 RTI International | ESAP
Kristin H. Gilchrist, PhD, Research Scientist Electonics and Applied Physics Division, RTI International

Panel Session

  • Tom Stanton, Executive Director, Danny Did Foundation
  • TBA
Moderator: Daniel Friedman, MD
Assistant Professor of Neurology, NYU, Comprehensive Epilepsy Center
3:30-3:45 Networking Break (15 minutes)

SESSION V: Late-Stage and Approved Devices--What is New?
3:45-3:55 Medtronic, Inc. | DBS Therapy for Epilepsy Jon Giftakis, PhD
3:55-4:05 NeuroSigma, Inc. | eTNS Leon Ekchian, PhD, President and CEO, NeuroSigma, Inc.

Christopher DeGiorgio, MD,
Professor of Neurology, UCLA
4:05-4:15 UCLA | Ultrasound for seizure modulation John Stern, MD, Director, Epilepsy Clinical Program, Co-Director, Seizure Disorder Center, Clinical Professor, Neurology, UCLA
4:15-4:25 Visualase, Inc. | Laser ablation in neurosurgery Bill Hoffman, CEO, Visualase, Inc.
4:25-4:35 Swedish Neuroscience Institute | MR-guided focused ultrasound for treatment of mesial TLE
John Snell, PhD, Technical Director-Brain Program, Focused Ultrasound Foundation
4:35-4:45 Children's Hospital Boston | TMS
Alexander Rotenberg, PhD, MD, Associate Professor of Neurology

SESSION VI: Nonprofit Organization, Government and Crowdfunding--Grants, Awards and Funding to Advance Research to the Next Critical Stage
4:45-5:45 Presentations and Panel Discussion
  • Panelists: Jan Buelow, PhD, Vice President Programs and Research
  • Rajesh Ranganathan, PhD, Director, Office of Translational Research, NINDS
  • TBA
  • TBA
Roger J. Porter, MD
, CSO, Epilepsy Foundation

Networking Reception and Lifetime Accelerator Award Celebration: Honoree To Be Announced!

Day 2-Friday June 6, 2014

7:00- 8:00 Networking Continental Breakfast

New Directions and Opportunities in Epilepsy Research

8:00- 8:30 New Directions in Epilepsy Research Daniel Lowenstein, MD, Professor, Neurology, UCSF School of Medicine
8:30-8:45 Improving Delivery of Therapies in People Who Need Them: An Industry Perspective Mark Evenstad, CEO, Upsher-Smith
8:45- 9:45 The Role of Corporate and Government Partnerships in Developing New Epilepsy Products | Presentations and Panel Discussion
Moderator: Roger J. Porter, MD
  What Does Big Pharma Look for in a New Drug for Epilepsy?
To Be Announced
  What Does Medium Sized Epilepsy-Oriented Pharma Look for in a New Drug for Epilepsy?
Michael Gold, MD, Vice-President, Global Therapeutic Area, CNS, UCB
  The Role of the NIH in Getting New Drugs to an IND
Rajesh Ranganathan, PhD, Director, Office of Translational Research, NINDS
  Collaboration in the Device Industry-How to Make it Work
Frank Fischer, CEO, NeuroPace
  Panel Discussion and Q&A  
9:45-10:00 Networking Break (15 minutes)

SESSION VIII: Clinical Stage Drugs

10:00-10:10 Ultragenyx Pharmaceutical Inc. | UX007G Emil D. Kakkis, MD, PhD, CEO, Ultragenyx Pharmaceutical Inc.
10:10-10:20 Alexza Pharmaceuticals | Inhaled Alprazolam
James V. Cassella, PhD, CSO and Executive Vice President, R&D, Alexza Pharmaceuticals, Inc.
10:20-10:30 Convergence Pharmaceuticals, Ltd | CNV1014802
Valerie Morisset, PhD, Head of Electrophysiology, Convergence Pharmaceuticals LTD
10:30-10:40 GW Pharmaceuticals | CBD
Geoffrey Guy, MD, Founder and Chairman, GW Pharmaceuticals

Harbor Therapeutics, Inc. | H3286

Clarence Ahlem, VP, Product Development, Harbor Therapeutics, Inc.
Insero Health | Huperzine Update
Stephen D. Collins, MD, PhD, President and CEO, Insero Health, Inc.
Marinus Pharmaceuticals, Inc. | Ganaxolone
Gail M. Farfel, PhD, Chief Clinical Development and Regulatory Officer, Marinus Pharmaceuticals, Inc.
SK LifeScience, Inc. | YKP 3089
Christopher Gallen, MD, PhD, President and CEO, SK Biopharmaceuticals | SK Life Sciences
UCB Pharma | Brivaracetam Update
Joseph D'Souza, Senior Global Medical Director, UCB Pharma
Vertex Pharmaceuticals | VX-765
Jacqueline French, MD, Professor of Neurology, New York University, Co-Director Epilepsy Research and Epilepsy Clinical Trials, NYU Comprehensive Epilepsy Center
11:40-12:00 To Be Announced
12:00-1:30 Networking Lunch and Poster Session (1 Hour, 30 Min.)

Who is Investing in Epilepsy and CNS Therapy Research and Innovation Today? Funding Beyond Angels, Grants and Awards

1:30-2:30 Panelists:
  • Greg Simon, CEO, Poliwogg
  • TBA
Moderator: Casey Lynch
Managing Director, NeuroInsights, LLC, Neurotechnology Industry Organization (NIO), CEO, Cortexyme, Inc.

SESSION X: Shark Tank Competition


Update: 2012 Shark Tank Winner | SAMi

Charles Anderson, HiPass Design LTD

Update: 2013 Shark Tank Winner | AED Drug Levels On A Chip Utkan Demirci, MS, PhD, Bio-Acoustic MEMS in Medicine Labs, Brigham and Women's Hospital, Harvard Medical Schook, Harvard-MIT Health Sciences and Technology
2:50-4:30 Moderator, Shark and Finalists: To Be Announced
Closing Remarks
Philip Gattone, President and CEO, Epilepsy Foundation
4:45-6:15 Light Networking Reception

FAMILY DAY: Day 3-Draft

Epilepsy: The Challenges of Today and Advances for Tomorrow
Saturday June 7, 2014, Registration
8:00-8:30 Registration
8:30-8:40 Introductions/Overview Patricia Osborne Shafer, RN, Associate Editor and Community Manager, Epilepsy Foundation: Beth Israel Deaconess Medical Center
8:40-9:00 Challenges of Epilepsy Elson So, MD, Mayo Clinic, President, American Epilepsy Society
9:00-9:15 Through Our Eyes To Be Announced
9:15-9:45 The Epilepsy Pipeline 2014
Roger J. Porter, MD, CSO, Epilepsy Foundation

Warren Lammert, Chairman, Epilepsy Foundation
9:45-10:00 Break
10:00-10:20 Chronic Seizure Medications Jacqueline French, MD, New York University
10:20-10:40 Rescue Therapies James Cloyd, PharmD, University of Minnesota
10:40-11:00 Medical Marijuana Jacqueline French, MD, New York University

Elizabeth Aquino, Writer, Parents/Family Advocate
Moving New Therapies into Practice Joseph Sirven, MD, Mayo Clinic Arizona, Editor-in-Chief,

Maureen Sheehan, CPNP, Child Neurology, Packard Children's Hospital at Stanford


Panel: Q and A

  • Jacqueline French, MD
  • James Cloyd, PharmD
  • Elizabeth Aquino
  • Maureen Sheehan, CPNP
Moderator: Joseph Sirven, MD, Mayo Clinic Arizona, Editor-in-Chief,
12:00-1:00 Lunch/Exhibits  
  Presentation Brandy E. Fureman, PhD, NINDS, NIH

Janice Buelow RN, PhD, Vice-President, Programs and Research, Epilepsy Foundation
1:00-1:20 When Seizures Don't Respond to Medications
Paul Garcia, MD, University of California San Francisco
1:20-1:40 New Approaches to Surgery Kurtis Auguste, MD, University of California San Francisco
1:40-2:10 Devices for Epilepsy
Robert Fisher MD, PhD, Stanford University School of Medicine

Panel Q and A

  • Paul Garcia, MD
  • Kurtis Auguste, MD
  • Robert Fisher, MD, PhD
  • Lisa Moss
Moderator: Patricia Dean, ARNP, MSN, Miami Children's Hospital Brain Institute
2:40-3:00 Break
3:00-3:25 Dietary Therapies Beth Zupec-Kania, RDN, CD, Ketogenic Therapies LLC
Stress, Seizures, and Exercise Alison Pack, MD, Columbia Presbyterian Medical Center

Panel Q and A

  • Beth Zupec-Kania, RDN, CD
  • Alison Pack, MD
  • Chanda Gunn
Moderator: To Be Announced
4:20-4:30 Wrap Up - Through Our Eyes Chanda Gunn
Ice Cream Social